Research programme: Kv1.3 potassium channel inhibitors - 4SC

Drug Profile

Research programme: Kv1.3 potassium channel inhibitors - 4SC

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4SC
  • Class Immunotherapies; Small molecules
  • Mechanism of Action Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 18 Jul 2017 Preclinical trials in Autoimmune disorders in Germany (PO)
  • 18 Jul 2017 4SC licences Kv1.3 potassium channel inhibitors to Maruho worldwide
  • 09 Oct 2013 Early research is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top